List of Excipients in Branded Drug MOXIDECTIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Medicines Development for Global Health	MOXIDECTIN	moxidectin	71705-050	ANHYDROUS LACTOSE	2032-02-07
Medicines Development for Global Health	MOXIDECTIN	moxidectin	71705-050	CELLULOSE, MICROCRYSTALLINE	2032-02-07
Medicines Development for Global Health	MOXIDECTIN	moxidectin	71705-050	CROSCARMELLOSE SODIUM	2032-02-07
Medicines Development for Global Health	MOXIDECTIN	moxidectin	71705-050	MAGNESIUM STEARATE	2032-02-07
Medicines Development for Global Health	MOXIDECTIN	moxidectin	71705-050	SILICON DIOXIDE	2032-02-07
Medicines Development for Global Health	MOXIDECTIN	moxidectin	71705-050	SODIUM LAURYL SULFATE	2032-02-07

Last updated: August 21, 2026

Moxidectin’s strongest excipient opportunity is a robust, low-cost oral platform that preserves single-dose convenience while improving dissolution, pediatric usability, taste, and tropical-climate stability. The commercial gap is less likely to be a new adult tablet and more likely to be a dispersible or multiparticulate product for children, mass drug administration, and markets where water access, humidity, and supply-chain conditions limit conventional tablets.

Moxidectin Excipient Strategy and Commercial Opportunities

What is the commercial profile of moxidectin?

Moxidectin is a macrocyclic lactone anthelmintic approved in the United States as an 8 mg oral tablet for the treatment of onchocerciasis caused by Onchocerca volvulus in patients at least 12 years old and weighing at least 30 kg. The product is administered as a single oral dose and was approved by the FDA in 2018 under NDA 210867.[1]

Moxidectin has several formulation-relevant characteristics:

Attribute	Commercial implication
Single-dose oral treatment	Supports simple tablet, dispersible tablet, or sachet presentations
High lipophilicity	Creates dissolution and absorption challenges
Long terminal half-life, approximately 20 to 30 days	Increases the importance of consistent exposure and food-effect control
Low dose, 8 mg adult strength	Allows compact dosage forms and multiparticulate delivery
Use in tropical and low-resource settings	Favors humidity-resistant packaging, low water dependence, and low manufacturing cost
Potential pediatric use	Creates demand for flexible dosing and age-appropriate administration
Neglected tropical disease indication	Requires procurement economics compatible with public-health programs

Moxidectin’s long systemic residence differentiates it from shorter-acting anthelmintics. A formulation that increases bioavailability without adequate control of dose uniformity could increase exposure variability and adverse-event risk. Excipient selection must therefore optimize dissolution without creating uncontrolled supersaturation or excessive food dependence.

What excipients are used in the approved moxidectin tablet?

The U.S. prescribing information identifies the approved 8 mg tablet’s inactive ingredients as lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and colloidal silicon dioxide.[1]

These excipients represent a conventional immediate-release platform:

Excipient	Functional role	Strategic assessment
Lactose monohydrate	Diluent and tablet mass builder	Cost-effective but requires attention to moisture, lactose intolerance claims, and supplier continuity
Microcrystalline cellulose	Filler and dry-binder	Supports direct compression and mechanical strength
Croscarmellose sodium	Superdisintegrant	Helps break up the tablet after ingestion
Magnesium stearate	Lubricant	Excessive use or over-lubrication can impair wetting and dissolution
Colloidal silicon dioxide	Glidant and flow aid	Improves powder flow and may reduce manufacturing variability

The listed excipients are widely accepted pharmaceutical materials. They do not, by themselves, create a strong differentiation barrier. Commercial value would come from a demonstrable improvement in dissolution, stability, administration, pediatric suitability, or manufacturing economics.

Which excipient strategies can improve moxidectin performance?

1. Amorphous solid dispersion

An amorphous solid dispersion could improve apparent solubility by placing moxidectin in a polymeric matrix. Candidate polymers may include hypromellose-based systems, hypromellose acetate succinate, polyvinylpyrrolidone, copovidone, or polyvinyl caprolactam-based polymers.

The principal development risks are physical recrystallization, moisture sensitivity, polymer-drug incompatibility, and excessive supersaturation followed by precipitation. A successful system would need comparative evidence against the approved tablet on:

• Dissolution across physiologically relevant pH conditions
• Solid-state stability
• Food-effect behavior
• Exposure and dose proportionality
• Storage under hot and humid conditions

An amorphous system could support a smaller tablet or lower-dose pediatric product. It could also create a formulation patent position if the claims cover a defined polymer ratio, solid-state form, dissolution profile, or manufacturing process.

2. Lipid-based delivery

Moxidectin’s lipophilicity makes lipid-based systems commercially relevant. Self-emulsifying drug delivery systems, soft-gel capsules, lipid-containing tablets, or lipid-loaded multiparticulates could improve wetting and solubilization.

Potential excipient classes include medium-chain triglycerides, mono- and diglycerides, polysorbates, poloxamers, phospholipids, and nonionic surfactants. The main limitations are:

• Higher excipient cost than a conventional tablet
• Potential food-effect changes
• Oxidative stability of lipid components
• Capsule-shell compatibility
• More complex process validation
• Less favorable logistics for mass drug administration

Lipid systems are better suited to a premium product, rescue formulation, or low-dose product with a clinically demonstrated exposure advantage than to a lowest-cost public-health tablet.

3. Wetting and precipitation-control systems

A simpler approach is to retain a conventional tablet but add a wetting agent or precipitation inhibitor. This may include a low level of surfactant, a polymeric precipitation inhibitor, or a redesigned disintegrant system.

This strategy has a lower manufacturing burden than a full amorphous dispersion. It may also reduce the regulatory burden if the product remains an immediate-release tablet with a comparable clinical profile. The commercial limitation is weaker differentiation unless the formulation shows a clear advantage in dissolution, bioavailability, or food independence.

4. Multiparticulates

Multiparticulates can support dose flexibility, taste masking, and improved administration for children. Moxidectin could be formulated as coated pellets, granules, minitablets, or powder for constitution.

Multiparticulate systems may use:

• Microcrystalline cellulose starter cores
• Hydroxypropyl cellulose or hypromellose binders
• Ethylcellulose or methacrylate polymers for coating
• Mannitol or sucrose-based carriers
• Silica or other flow aids
• Flavoring and sweetening systems for oral administration

The principal technical issue is dose uniformity. Because moxidectin is administered at a low mass, drug layering and segregation must be tightly controlled. A multiparticulate product also needs packaging that limits moisture ingress and prevents loss of flow or agglomeration.

What pediatric formulation opportunities exist for moxidectin?

The approved U.S. product is not positioned as a pediatric formulation for children below 12 years or below 30 kg.[1] A pediatric product could expand use in endemic regions, but it would require more than a smaller tablet.

The most commercially relevant formats are:

Format	Advantages	Key barriers
Dispersible tablet	Low shipping cost, no liquid supply chain, suitable for water-based administration	Taste, dispersion time, dose flexibility
Oral granules or powder	Flexible dosing and potential sachet packaging	Segregation, moisture, content uniformity
Mini-tablets	Precise unit dosing and child-friendly administration	Swallowability and dose assembly
Oral suspension	Familiar administration and flexible dosing	Preservatives, stability, shipping volume, microbial control
Orally disintegrating tablet	Rapid administration without water	Taste masking, friability, packaging cost

A dispersible tablet is the strongest balance of cost and public-health utility. It can be supplied in foil-based unit-dose blisters or sachets and administered with a small volume of water. Mannitol, microcrystalline cellulose, crospovidone, croscarmellose sodium, and low-moisture sweetening systems are potential excipient components. Flavor masking would be necessary if the active ingredient has an unacceptable bitter or persistent taste.

A pediatric formulation should be tested for dose preparation errors, especially where caregivers may divide tablets, mix powder with food, or use variable water volumes. The product should be designed around simple instructions and minimal preparation steps.

What manufacturing and stability barriers affect excipient selection?

Moxidectin products intended for Africa, Latin America, or other tropical regions require stability programs that reflect high temperature and humidity. Excipient choices should be evaluated under ICH climatic conditions and in packaging that limits water vapor transmission.[2]

Important risks include:

• Moisture-driven loss of tablet hardness
• Croscarmellose or crospovidone performance changes
• Lactose-related impurity formation with reactive amines
• Lubricant overuse that reduces dissolution
• Polymer plasticization in amorphous dispersions
• Oxidation of lipid excipients
• Excipient variability affecting powder flow
• Drug segregation in low-dose blends

For a public-health product, the preferred manufacturing platform is likely direct compression or dry granulation using globally available excipients. Spray drying, hot-melt extrusion, and lipid filling may improve drug performance but can reduce the number of qualified manufacturers and increase capital requirements.

Packaging is part of the excipient strategy. High-barrier aluminum-aluminum blister packs or foil sachets may be more valuable than a marginal change in tablet composition. Bottles can reduce cost in some markets but introduce moisture exposure after opening and may be less suitable for single-dose distribution.

What formulation patents could protect a differentiated moxidectin product?

The approved active ingredient is an older anthelmintic, and commercial protection is more likely to arise from formulation, use, manufacturing, or combination claims than from basic composition-of-matter rights.

Potential claim categories include:

1. A defined moxidectin-polymer amorphous dispersion.
2. A lipid composition that produces a specified dissolution or exposure profile.
3. A dispersible pediatric dosage form with defined disintegration and dose-uniformity parameters.
4. A taste-masked granule or multiparticulate system.
5. A solid dosage form with reduced food-effect variability.
6. A manufacturing process that produces a stable amorphous or crystalline form.
7. A fixed-dose combination with another anthelmintic.
8. A packaging and dosage regimen designed for mass drug administration.

Patent strength would depend on whether the formulation solves a measurable technical problem. Broad claims covering routine excipients are vulnerable to obviousness attacks. Narrow claims supported by comparative pharmacokinetic, stability, or dissolution data are more defensible.

The U.S. product’s FDA labeling identifies the approved formulation and regulatory status, but a detailed freedom-to-operate review must separately assess issued patents, pending applications, national-phase filings, and rights held by the originator, development partners, and excipient-technology providers.[1,3]

What is the Orange Book status and generic-entry outlook for moxidectin?

Moxidectin was approved in 2018 and received FDA Priority Review under the tropical disease pathway. The FDA also awarded a tropical disease priority review voucher to Medicines Development for Global Health following approval.[4]

The principal regulatory considerations are:

Issue	Assessment
Reference product	Moxidectin 8 mg tablet
FDA approval date	June 13, 2018
Exclusivity	The five-year new chemical entity period would generally run from approval, subject to the exact regulatory designation and any applicable extensions
Orphan exclusivity	The onchocerciasis indication should not be assumed to have orphan-drug exclusivity without a specific FDA orphan designation
Orange Book patents	Patent listing status should be confirmed from the current FDA Orange Book and patent-listing records
Paragraph IV risk	Most relevant if an active listed patent covers the reference product or an approved method of use
Generic pathway	An ANDA could be viable if the applicant can establish pharmaceutical equivalence, bioequivalence, and acceptable impurity and dissolution profiles
Pediatric product pathway	A new dosage form or strength may require a separate NDA, supplement, or 505(b)(2) strategy depending on the formulation and reliance position

Moxidectin is a small-molecule drug, so biosimilar risk is not relevant. Competitive risk comes from conventional generics, improved formulations, alternative anthelmintics, and procurement contracts rather than biosimilars.

A formulation with a new dosage form, enhanced bioavailability, or pediatric indication could support a 505(b)(2) application if it relies in part on the approved product while presenting new clinical or pharmaceutical data. Patent protection would need to cover the differentiated formulation or use, rather than merely restating the known active ingredient.

Which companies and markets offer the strongest commercial opportunities?

The principal commercial stakeholders are Medicines Development for Global Health, public-health procurement agencies, generic manufacturers, contract development and manufacturing organizations, and excipient suppliers.

The largest near-term opportunities are likely to be:

• Low-cost dispersible tablets for mass drug administration
• Pediatric granules or mini-tablets for children below the current U.S. labeled population
• Stable products for high-temperature and high-humidity markets
• Contract manufacturing platforms based on direct compression or dry granulation
• Taste-masked products that enable administration without swallowing a conventional tablet
• Fixed-dose or co-packaged anthelmintic programs
• Formulations with validated dose flexibility for weight-based use

The commercial case is strongest where the formulation reduces administration cost or expands the treatable population. A premium lipid or amorphous-dispersion product would require evidence of a clinically meaningful benefit, such as lower dose, reduced food dependence, faster onset, or improved exposure consistency.

How does moxidectin compare with ivermectin on formulation strategy?

Factor	Moxidectin	Ivermectin
Therapeutic class	Macrocyclic lactone	Macrocyclic lactone
U.S. approved onchocerciasis presentation	8 mg tablet	Multiple oral tablet products and other formulations globally
Dosing profile	Single-dose treatment with long persistence	Repeated or weight-based use depending on indication
Formulation priority	Exposure control, pediatric flexibility, dissolution improvement	Broad dosage-form access and large-scale generic supply
Excipient opportunity	Dispersible, multiparticulate, amorphous, taste-masked systems	Pediatric liquids, topical systems, fixed-dose and combination products
Generic competition	More limited relative to ivermectin	Mature and extensive
Differentiation potential	Higher for pediatric and public-health dosage forms	More dependent on cost, delivery route, and indication

Moxidectin has greater opportunity for differentiated delivery because its approved commercial platform is narrower. Ivermectin has a deeper generic and manufacturing ecosystem, which raises price competition but lowers supply-chain risk.

What generic launch scenarios exist for moxidectin?

Three scenarios are commercially plausible.

Conventional tablet entry

A generic manufacturer could target the 8 mg immediate-release tablet using a conventional excipient system. The main barriers would be bioequivalence, dissolution, manufacturing scale, and access to a reliable active pharmaceutical ingredient source.

Formulation-led entry

A company could develop a dispersible, orally disintegrating, or multiparticulate product. This would create a broader regulatory and clinical package but could support pediatric expansion, new procurement contracts, and formulation patents.

Public-health partnership entry

A nonprofit or generic manufacturer could pursue a cost-optimized product for endemic countries. The value proposition would rely on procurement volume, simple manufacturing, high-barrier packaging, and distribution partnerships rather than premium pricing.

A Paragraph IV challenge would be relevant only where current listed patents create a legal barrier. The commercial attractiveness of such a challenge depends on the remaining market, the enforceability of any formulation or method-of-use patents, and whether the reference product has meaningful U.S. sales.

How strong is the moxidectin excipient opportunity?

The excipient opportunity is moderate for the adult tablet and strong for pediatric and public-health formulations.

The approved tablet uses standard excipients, so a competitor is unlikely to obtain durable differentiation by substituting one conventional filler or disintegrant for another. Stronger opportunities require a defined performance advantage:

• Faster or more complete dissolution
• Lower variability under fed and fasted conditions
• Improved physical stability
• Flexible dosing below 8 mg
• Acceptable taste
• Reduced preparation burden
• Compatibility with tropical distribution
• Lower manufacturing cost at scale

The highest-value development program would combine a dispersible or multiparticulate platform with taste masking, moisture-resistant packaging, and a regulatory strategy that supports pediatric or weight-flexible dosing.

Key Takeaways

• Moxidectin is approved in the United States as an 8 mg single-dose tablet for onchocerciasis in patients at least 12 years old and weighing at least 30 kg.[1]
• The approved excipient system is conventional: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and colloidal silicon dioxide.
• The central formulation challenge is improving dissolution and exposure control without creating excessive food dependence or instability.
• Amorphous solid dispersions and lipid systems have technical potential but may be too expensive for mass drug administration.
• Dispersible tablets, granules, and multiparticulates offer the strongest commercial opportunity for pediatric and endemic-market expansion.
• Formulation patents should focus on measurable performance, including dissolution, stability, dose uniformity, taste masking, or reduced food effect.
• Moxidectin has small-molecule generic risk, not biosimilar risk.
• Orange Book and patent-listing status must be evaluated against the current FDA records before a Paragraph IV or launch decision.
• High-barrier packaging may provide as much commercial value as a new excipient composition in tropical markets.
• Compared with ivermectin, moxidectin has a narrower existing dosage-form ecosystem and greater scope for delivery-system differentiation.

FAQs About Moxidectin Excipients and Commercial Formulation

Can moxidectin be made into an oral suspension?

Yes. An oral suspension could improve dose flexibility, but it would require control of sedimentation, redispersibility, taste, preservative effectiveness, microbial quality, and chemical stability. A dry powder for reconstitution may be more suitable for tropical distribution than a ready-to-use liquid.

Which excipient is most important for moxidectin dissolution?

No single conventional excipient is likely to resolve the full dissolution challenge. The highest-impact approach would usually combine particle-size control or an amorphous dispersion with an effective disintegrant and wetting system.

Is a moxidectin fixed-dose combination commercially attractive?

Potentially. A combination with another anthelmintic could support broader parasite coverage or coordinated public-health treatment, but compatibility, dose scheduling, safety, and regulatory evidence would determine feasibility.

Does moxidectin require a biosimilar strategy?

No. Moxidectin is a chemically synthesized small molecule. Market entrants would generally evaluate an ANDA, a 505(b)(2) application, or a standalone product strategy rather than a biosimilar pathway.

What is the best packaging for moxidectin in tropical markets?

A high-barrier unit-dose blister or foil sachet is generally the strongest option for protecting a low-dose solid dosage form from humidity and simplifying distribution. The final choice depends on stability data, procurement requirements, and packaging-line economics.

References

1. U.S. Food and Drug Administration. (2018). Moxidectin tablets, for oral use: Prescribing information. Medicines Development for Global Health.

2. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. ICH.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2018). FDA approves new treatment for river blindness and awards tropical disease priority review voucher. U.S. Department of Health and Human Services.